13 September 2019
Consilium Strategic Communications advises Achilles Therapeutics on its successful £100 million oversubscribed Series B financing
London, 9 September 2019, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, on communications activities surrounding its recent £100 million oversubscribed Series B financing.
Achilles is a biopharmaceutical company leading the next wave of immune-oncology drug development using T cell therapies to target neoantigens in non-small cell lung cancer and melanoma. The company’s pioneering technology allows individualised treatments to potentially target and destroy tumours without harming healthy tissue. Proceeds from this financing will enable the delivery of two human proof-of-concept studies using a personalised T cell therapy approach in non-small cell lung cancer and melanoma, expected to enter the clinic this year. Additionally, the financing will help progress the solid-tumour pre-clinical product pipeline as well as increasing the company’s manufacturing capabilities.
“We are delighted to have advised Achilles on their financial and strategic communications in this highly successful series B fundraising. Achilles’ pioneering approach to tackling cancer is moving rapidly into the clinic and we are excited to continue to work closely with the company as it executes on its strategy.”
Sukaina VirjiSenior Associate Partner at Consilium Strategic Communications
To view Achilles’ announcement please visit: https://achillestx.com/
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across al areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.
About Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.
Achilles was founded by lead investor Syncona Ltd and its original shareholders include the CRT Pioneer Fund, UCL Technology Fund, Cancer Research Technology, with the support of UCL Business (UCLB) and the Francis Crick Institute. For further information please visit the Company’s website at: www.achillestx.com